Reference
Sehested TSG, et al. Cost-effectiveness of canakinumab to prevent recurrent cardiovascular events. ESC Congress 2018: Annual Congress of the European Society of Cardiology : abstr. P2562, 25 Aug 2018. Available from: URL: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-3-Health-economics/176944-cost-effectiveness-of-canakinumab-to-prevent-recurrent-cardiovascular-events#abstract
Rights and permissions
About this article
Cite this article
Canakinumab not cost effective for secondary prevention. PharmacoEcon Outcomes News 812, 10 (2018). https://doi.org/10.1007/s40274-018-5277-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5277-4